Conviction
1 → 4
Conviction●●●●○4 of 5
Research target$269.15Snapshot target
Thesis statusSTRENGTHENEDLast reviewed 7/8/26
Market cap$34.69BSnapshot value
Research history
See all IQV changes ↗What changed
Target
— → $269.15
Thesis status
NEEDS_MORE_DATA → STRENGTHENED
Last reviewed
Not reviewed → 7/8/26
Target
— → $269.15
Conviction
1 → 4
Full-service CRO + RWD/RWE data moat. Multi-year contracts and backlog insulate. Largest health-data catalog creates a durable competitive advantage. Paid to run trials regardless of outcome.
R&D funding at decade highs (~$102B in 2024); RWE regulatory acceptance for approvals/labels; AI-clinical analytics partnership (Veeva) expanding service scope; BIOSECURE reshoring tailwind.
Biotech funding volatility (hits small-client-levered CROs first); elevated cancellations/rebids; part of multiple rides AI-analytics narrative — not purely decoupled; China exposure.
needs X/Reddit sentiment sweep
Snapshot · 7/8/26🟢 Lean-Bull · 13F 18+/7- · short↑0.3
Snapshot · 7/8/26